abstract |
Provided are novel interleukin-20 (IL-20) binding molecules of human origin, particularly human-derived anti-human IL-20 antibodies as well as IL-20 binding fragments, derivatives and biotechnological derivatives thereof. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy are described. In addition, a cellular enzyme-linked ligand binding assay is described for isolating antibodies and biotechnological derivatives thereof for pharmaceutical use, in particular recombinant human-derived anti-human cytokine antibodies. |